A376s in the connection subdomain of HIV-1 reverse transcriptase confers increased risk of virological failure to nevirapine therapy
- R. Paredes
- M.C. Puertas
- W. Bannister
- M. Kisic
- A. Cozzi-Lepri
- C. Pou
- R. Bellido
- G. Betancor
- J. Bogner
- P. Gargalianos
- D. Banhegyi
- B. Clotet
- J. Lundgren
- L. Menendez-Arias
- J. Martinez-Picado
- M. Losso
- C. Elias
- N. Vetter
- R. Zangerle
- I. Karpov
- A. Vassilenko
- V.M. Mitsura
- O. Suetnov
- N. Clumeck
- S. De Wit
- B. Poll
- R. Colebunders
- L. Vandekerckhove
- V. Hadziosmanovic
- K. Kostov
- J. Begovac
- L. Machala
- H. Rozsypal
- D. Sedlacek
- J. Nielsen
- G. Kronborg
- T. Benfield
- M. Larsen
- J. Gerstoft
- T. Katzenstein
- A.-.E. Hansen
- P. Skinhoj
- C. Pedersen
- L. Oestergaard
- K. Zilmer
- J. Smidt
- M. Ristola
- C. Katlama
- J.-. Viard
- P.-. Girard
- J.M. Livrozet
- P. Vanhems
- C. Pradier
- F. Dabis
- D. Neau
- J. Rockstroh
- R. Schmidt
- J. Van Lunzen
- O. Degen
- H.J. Stellbrink
- S. Staszewski
- J. Bogner
- G. Fatkenheuer
- J. Kosmidis
- P. Gargalianos
- G. Xylomenos
- J. Perdios
- G. Panos
- A. Filandras
- E. Karabatsaki
- H. Sambatakou
- D. Banhegyi
- F. Mulcahy
- I. Yust
- D. Turner
- M. Burke
- S. Pollack
- G. Hassoun
- S. Maayan
- S. Vella
- R. Esposito
- I. Mazeu
- C. Mussini
- C. Arici
- R. Pristera
- F. Mazzotta
- A. Gabbuti
- V. Vullo
- M. Lichtner
- A. Chirianni
- E. Montesarchio
- M. Gargiulo
- G. Antonucci
- F. Iacomi
- P. Narciso
- C. Vlassi
- M. Zaccarelli
- A. Lazzarin
- R. Finazzi
- M. Galli
- A. Ridolfo
- A. D&apos
- B. Rozentale
- P. Aldins
- S. Chaplinskas
- R. Hemmer
- T. Staub
- P. Reiss
- V. Ormaasen
- A. Maeland
- J. Brunn
- B. Knysz
- J. Gasiorowski
- A. Horban
- E. Bakowska
- D. Prokopowicz
- R. Flisiak
- A. Boron-Kaczmarska
- M. Pynka
- M. Beniowski
- E. Mularska
- H. Trocha
- E. Jablonowska
- E. Malolepsza
- K. Wojcik
- F. Antunes
- E. Valadas
- K. Mansinho
- F. Maltez
- D. Duiculescu
- A. Rakhmanova
- E. Vinogradova
- S. Buzunova
- D. Jevtovic
- M. Mokras
- D. Stanekova
- J. Tomazic
- J. Gonzalez-Lahoz
- V. Soriano
- L. Martin-Carbonero
- P. Labarga
- S. Moreno
- B. Clotet
- A. Jou
- R. Paredes
- C. Tural
- J. Puig
- I. Bravo
- J.M. Gatell
- J.M. Miro
- P. Domingo
- M. Gutierrez
- G. Mateo
- M. Sambeat
- A. Karlsson
- P.O. Persson
- L. Flamholc
- B. Ledergerber
- R. Weber
- P. Francioli
- M. Cavassini
- B. Hirschel
- E. Boffi
- H. Furrer
- M. Battegay
- L. Elzi
- E. Kravchenko
- N. Chentsova
- G. Kutsyna
- S. Servitskiy
- M. Krasnov
- S. Barton
- A.M. Johnson
- D. Mercey
- A. Phillips
- M.A. Johnson
- A. Mocroft
- M. Murphy
- J. Weber
- G. Scullard
- M. Fisher
- C. Leen
- J. Gatell
- B. Gazzard
- J. Lundgren
- O. Kirk
- A. Cozzi-Lepri
- D. Grint
- M. Ellefson
- D. Podlekareva
- J. Kjaer
- L. Peters
- J. Reekie
- J. Kowalska
- J. Tverland
- A.H. Fischer
DOIAbstract
Background. The clinical relevance of mutations in the connection subdomain and the ribonuclease (RNase) H domain of HIV-1 reverse transcriptase (RT) is uncertain. Methods. The risk of virological failure to nonnucleoside RT inhibitor (NNRTI)-based antiretroviral therapy (ART) was evaluated in NNRTI-naive patients who started NNRTIs in the EuroSIDA study after July 1997 according to preexisting substitutions in the connection subdomain and the RNase H domain of HIV-1 RT. An observed association between A376S and virological failure was further investigated by testing in vitro NNRTI susceptibility of single site-directed mutants and patient-derived recombinant viruses. Enzymatic assays also determined the effects of A376S on nevirapine and t...
Add to ORKG